Treatment of Klebsiella Infections

Introduction to Klebsiella Infections

Klebsiella infections require prompt and effective treatment, with consideration of risk factors such as previous antibiotic exposure, hospitalization, and nursing home residence 1, 2, 3

The Infectious Diseases Society of America recommends carbapenems (meropenem, imipenem, ertapenem) as the most effective first-line antibiotics for Klebsiella infections, particularly for serious infections or when extended-spectrum beta-lactamase (ESBL) production is suspected 4, 5, 6
The American College of Physicians recommends using Group 2 carbapenems (meropenem, imipenem) as first-line treatment for patients with septic shock, ICU admission, or suspected Pseudomonas involvement 2, 3, 4

For severe or life-threatening infections, such as sepsis or pneumonia, carbapenems are the first choice, and combination therapy may be necessary for carbapenem-resistant strains 6
Intra-abdominal infections caused by ESBL-producing bacteria should be treated with carbapenems when suspected, with a treatment duration of 7-10 days (up to 14 days for nosocomial infections) 3

The World Journal of Emergency Surgery guidelines suggest meropenem (1g every 8 hours) or combination therapy with piperacillin-tazobactam plus tigecycline for intra-abdominal infections 4

For bacteremia caused by ESBL-producing Klebsiella, carbapenems are recommended, with a treatment duration of 7-14 days 7

The recommended treatment duration for urinary tract infections (UTIs) depends on the complexity of the infection, with recommended durations including:
Infection Type Recommended Treatment Duration
Uncomplicated cystitis 5-7 days
Complicated UTI 7-14 days
Pyelonephritis 10-14 days
8, 6, 4
For complicated UTIs caused by carbapenem-resistant Enterobacteriaceae (CRE), treatment options include Meropenem-vaborbactam (4g IV q8h) or Imipenem-cilastatin-relebactam (1.25g IV q6h), as recommended by the Infectious Diseases Society of America, and Ceftazidime-avibactam (2.5g IV q8h) or Plazomicin (15 mg/kg IV q12h), as stated by the Journal of Microbiology, Immunology and Infection 9
Single-dose aminoglycoside can be effective for simple cystitis due to CRE, as reported by the Journal of Microbiology, Immunology and Infection 9

Infection Type	Recommended Treatment Duration
Uncomplicated cystitis	5-7 days
Complicated UTI	7-14 days
Pyelonephritis	10-14 days

The Clinical Infectious Diseases guidelines recommend de-escalating therapy once susceptibility results are available, and avoiding fluoroquinolones for empiric therapy in areas with high resistance rates 7
Empiric therapy for suspected ESBL infections should generally include carbapenem coverage, with de-escalation if susceptibility testing allows, and the Infectious Diseases Society of America recommends avoiding fluoroquinolones for empiric therapy in nursing home patients with suspected ESBL infections due to high resistance rates among ESBL producers and the risk of selecting for further resistance 1

Combination therapy may be beneficial for critically ill patients with carbapenem-resistant Klebsiella infections, and should not be delayed in suspected resistant cases, as mortality increases significantly with inappropriate initial therapy 6, 7

Cephalosporins alone should not be relied upon for ESBL-producing strains, even if they appear susceptible in vitro, and monotherapy with colistin or tigecycline should not be used for severe infections 6, 7, 10
The World Health Organization and other health organizations imply that fluoroquinolones should be avoided for empiric therapy due to high resistance rates among ESBL producers (60-93%), and urine culture and susceptibility testing are recommended for all suspected ESBL infections to guide definitive therapy, as suggested by the European Urology guidelines 8, 4

Active surveillance in patients at risk to identify colonized patients and prevent dissemination is recommended, according to the World Journal of Emergency Surgery guidelines, and contact precautions are strongly recommended for all ESBL-producing Enterobacteriaceae except E. coli, according to the Clinical Microbiology and Infection guidelines 11, 12
Avoid unnecessary broad-spectrum antibiotics to prevent further resistance development, as recommended by the World Journal of Emergency Surgery guidelines, and monitoring for resistance development during therapy is essential, particularly with ESBL-producing organisms, to guide early appropriate therapy and prevent the selection of carbapenem-resistant organisms, as recommended by the World Journal of Emergency Surgery and Clinical Microbiology and Infection guidelines 3, 6, 4

Resistance rates vary by region, with China, India, Thailand, and Vietnam having fluoroquinolone resistance rates among E. coli isolates exceeding 20%, while Taiwan has lower rates of fluoroquinolone resistance (<20%) among E. coli isolates, and levofloxacin resistance in H. influenzae increased significantly in Taiwan from 2.0% in 2004 to 24.3% in 2010 13, 14, 15